AmCyte to Present Successful Regenerated Islet Data at the 64th Annual Scientific Conference of the American Diabetes Association.Business Editors/Health/Medical Writers BIOWIRE2K LOS ANGELES--(BUSINESS WIRE)--June 1, 2004 AmCyte Inc. (www.amcyte.com), a leader in encapsulated islet islet /is·let/ (-lit) an island. islets of Langerhans irregular microscopic structures scattered throughout the pancreas and comprising its endocrine portion. replacement and pancreatic adult stem cells, announced it will present research data from its regenerated islet program at the 64th Annual Scientific Conference of the American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of to be held in Orlando Florida, June 4-8, 2004 (www.diabetes.org/am04). AmCyte will be presenting data from its Regenerated Islet Program, which aims to create a transplantable supply of islets for the diabetes patient community. AmCyte's studies show how pancreatic cells can be expanded in culture and treated to resume function and appearance similar to those of isolated Islets of Langerhans islets of Langerhans: see pancreas. . The Regenerated Islet Program along with AmCyte's encapsulation (1) In object technology, the creation of self-contained modules that contain both the data and the processing. See object-oriented programming. (2) The transmission of one network protocol within another. technology will allow AmCyte to move towards its goal of transplanting regenerated islets into patients with diabetes without immune suppression. AmCyte's encapsulation technology protects transplanted islets from immune destruction and allows physicians to transplant islets without immune suppression. The data to be presented show: -- AmCyte is able to expand pancreatic islet cells in culture; -- Encapsulated Regenerated Islets produce insulin and show islet-like function; -- Encapsulated Regenerated Islets are able to successfully treat diabetic mice and normalize normalize to convert a set of data by, for example, converting them to logarithms or reciprocals so that their previous non-normal distribution is converted to a normal one. their blood glucose blood glucose Diabetology The principal sugar produced by the body from food–especially carbohydrates, but also from proteins and fats; glucose is the body's major source of energy, is transported to cells via the circulation and used by cells in the presence . "This exciting data was made possible by the efforts of our excellent scientific team and is a step in the right direction," said Dr. Wen Tsang, AmCyte's Senior Vice President, Research & Development. "We are currently focusing on increasing this expansion of pancreatic cells to be able to treat many patients from a single donor pancreas." AmCyte's data will be on display at the conference in the main Exhibit Hall from Saturday June 5th through Monday June 7th in the Transplantation category. AmCyte Inc., located in Santa Monica, California For other uses, see Santa Monica (disambiguation). Santa Monica is a coastal city in western Los Angeles County, California, USA. Situated on Santa Monica Bay of the Pacific Ocean, it is surrounded by the City of Los Angeles — Pacific Palisades and Brentwood on the north, , specializes in islet transplantation therapy to treat diabetes. AmCyte has developed novel encapsulation technology to allow transplantation of insulin-producing islets without chronic immune suppression. The company is developing Regenerated Islets utilizing its proprietary adult stem cell technology to scale up the supply of transplantable islets to meet clinical trial and patient needs. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion